News
Format – Fireside chat and one-on-one investor meetings Date and Time – Wednesday, June 11, 2025, at 8:40am ET / 5:40am PT Live webcasts of the data release, as well as the presentation ...
a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June 3, 2025, at 4:15pm ET / 1:15pm PT. During the webcast, members of Anaptys management ...
PD-1 inhibitors work by blocking the PD-1 (programmed death-1) receptor on T cells, preventing cancer cells from evading the immune system and restoring the body's ability to fight cancer. Combining ...
mediated by engagement of PD-1 by PD-L1 and PD-L2. The structural conservation of B7-like and CD28-like receptors may reflect the distance between T cells and APCs in the immunological synapse.
Two-part preclincal and clinical development programme launched to assess potential benefits of administering S-pindolol benzoate during and post-GLP-1 receptor agonist therapy to improve muscle ...
AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...
AnaptysBio offers significant upside, with fair value estimates nearly double its current market cap if RA approval is ...
Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that its third drug candidate, RM-0256, has been ...
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results